Evidence map›Paper›PMID 42399987›Full record

ArticleBehavioral and brain functions : BBF2026

Impact of clomipramine postnatal exposure on sexual behavior and reproductive organs in female rats: role of sexual experience.

Tania Molina-Jiménez, Nora Guzmán Lozada, Mayvi Alvarado, Claudia Juárez-Portilla, Rossana C Zepeda, José A Sánchez-Salcedo, Mónica Flores-Muñoz, Herlinda Bonilla-Jaime

Abstract read
In one paragraph

Article in Behavioral and brain functions : BBF, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tania Molina-Jiménez *Laboratory of Integral Biomedicine and Health, Biomedical Research Center, Universidad Veracruzana, Xalapa, Veracruz, Mexico. tmolina@uv.mx.ORCID http://orcid.org/0000-0001-5236-6838
Nora Guzmán LozadaLaboratory of Integral Biomedicine and Health, Biomedical Research Center, Universidad Veracruzana, Xalapa, Veracruz, Mexico.
Mayvi AlvaradoInstitute of Neuroethology, Universidad Veracruzana, Xalapa, Veracruz, Mexico.
Claudia Juárez-PortillaLaboratory of Neurobiology of Behavior and Neurochemical Processes, Biomedical Research Center, Universidad Veracruzana, Xalapa, Veracruz, Mexico.
Rossana C ZepedaLaboratory of Molecular Diagnostics, Biomedical Research Center, Universidad Veracruzana, Xalapa, Veracruz, Mexico.
José A Sánchez-SalcedoFaculty of Agricultural Production Systems Engineering, Universidad Veracruzana, Acayucan, Veracruz, Mexico.
Mónica Flores-MuñozLaboratory of Translational Medicine, Institute of Health Sciences, Universidad Veracruzana, Acayucan, Veracruz, Mexico.
Herlinda Bonilla-Jaime *Laboratory of Behavioral and Reproductive Biology, Department of Reproductive Biology, Universidad Autónoma Metropolitana- Iztapalapa, Ciudad de México, C.P, 55 535, 09340, México. bjh@xanum.uam.mx.

Funding

Estancia Posdoctoral Vinculada al Fortalecimiento de la Calidad del Posgrado Nacional program granted by Mexico's Consejo Nacional de Ciencia y Tecnología (CONACyT) COVIA-0890-2016Research Assistant fellowship SNI 53014 granted by CONACyT SNI 53014
6 · The paper itself

Abstract

Depression is a common psychiatric disorder during pregnancy and the postnatal period. Consequently, antidepressant treatment is primordial for the safety of the mother and the neonate. Clomipramine (CMI) is a tricyclic antidepressant that has been prescribed even when the evidence suggests potential adverse effects on the neurodevelopment of the offspring, considering that antidepressant drugs can be transferred through breast milk. Nevertheless, in some cases, when the benefits outweigh the risks, it is used to treat severe depression in pregnant women. In rodents, postnatal administration of CMI causes persistent behavioral and neurophysiological alterations in adulthood. By contrast, a rewarding experience, such as mating, improves motivational and copulatory behavior in rodents through neuroplasticity in brain structures involved in reproduction. In a previous work, we reported that postnatal exposure to CMI disrupts the motivational and copulatory components of female sexual behavior during a single copulatory test. Therefore, the purpose of this study was to examine the effects of postnatal CMI treatment on female sexual behavior and reproductive tissues, and to determine whether sexual experience serves as a modulatory factor that ameliorates its potential impact on sexual performance. Female pups were divided in two groups, CMI group (30 mg/Kg) and the control group (NaCl 0.9%). Each group received a daily subcutaneous injection with CMI or saline solution from the 8th to 21st postnatal days. Behavioral test and histological analysis were performed at 3 months of age. The results indicated that postnatal CMI administration disrupts receptive but not proceptive behaviors. Repeated sexual encounters with males partially reversed the receptivity impairment in CMI-treated females, as it occurs in control rats. Histological data showed that CMI reduces the population of primordial and primary follicles; however, no morphological modifications were detected in the uterine layers. In conclusion, the data show that even when sexual experience partially improved copulatory behavior in female rats exposed to CMI during the postnatal period, ovarian development was affected, which could compromise fertility.

Indexed as

Antidepressive Agents, TricyclicClomipramineSexual Behavior, AnimalAnimalsAnimals, NewbornCopulationFemalePregnancyRatsRats, WistarAntidepressive Agents, TricyclicClomipramineAntidepressantsClomipramineDepressionOvarian folliclesPostnatal exposureSexual experienceUterus

Identifiers

PMID42399987
PMCPMC13617766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.